Cellectis (CLLS) news
Recent news
Cellectis - final Phase 1 Balli-1 data for Lasme-Cel to be presented June 13, 2026
Cellectis, a clinical-stage biotechnology company, is set to present final Phase 1 data for its CD22-directed allogeneic CAR-T therapy, Lasme-cel, at the EHA annual congress on June 13 . The data will be presented orally by Nitin Jain, M.D., from MD Anderson Cancer Center, during a session on…
AInvest Wire · Jun 9, 2026Allogene Therapeutics names Zachary Roberts as CEO
Allogene Therapeutics, Inc. (Nasdaq: ALLO) has appointed Zachary J. Roberts, M.D., Ph.D., as Executive Vice President of Research and Development, a role that includes oversight of the company’s clinical and pre-clinical programs. Dr. Roberts succeeds Rafael Amado, M.D., who has stepped down to…
AInvest Wire · May 28, 2026Cellectis Q1 Adj $(0.14) Beats $(0.33) Estimate, Sales $6.50M Beat $3.70M Estimate
Cellectis Q1 Adj $(0.14) Beats $(0.33) Estimate, Sales $6.50M Beat $3.70M Estimate The biotech industry witnessed a remarkable performance from Cellectis (NASDAQ: CLCS) in the first quarter, as the company reported adjusted earnings per share (EPS) of $0.14, surpassing analysts' expectations of…
AInvest Wire · May 28, 2024ImportantAstraZeneca completes equity investment agreement with Cellectis
AInvest Wire · May 6, 2024ImportantCellectis rockets 100% premarket after announcing to team up with AstraZeneca on cell, gene therapy products
AInvest Wire · Nov 1, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.